Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Change in Accured Expenses (2019 - 2026)

Pliant Therapeutics has reported Change in Accured Expenses over the past 8 years, most recently at -$6.5 million for Q1 2026.

  • Quarterly Change in Accured Expenses fell 34.65% to -$6.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$13.8 million through Mar 2026, down 15101.1% year-over-year, with the annual reading at -$12.2 million for FY2025, 419.6% down from the prior year.
  • Change in Accured Expenses was -$6.5 million for Q1 2026 at Pliant Therapeutics, down from -$1.5 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $5.8 million in Q2 2022 and troughed at -$6.5 million in Q1 2026.
  • The 5-year median for Change in Accured Expenses is -$538000.0 (2023), against an average of -$244058.8.
  • Year-over-year, Change in Accured Expenses soared 659.95% in 2022 and then plummeted 976.68% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$411000.0 in 2022, then soared by 270.07% to $699000.0 in 2023, then plummeted by 976.68% to -$6.1 million in 2024, then surged by 75.29% to -$1.5 million in 2025, then tumbled by 327.61% to -$6.5 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Change in Accured Expenses are -$6.5 million (Q1 2026), -$1.5 million (Q4 2025), and -$2.0 million (Q3 2025).